HTML Microdata document

This HTML5 document contains 30 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
rdfs	http://www.w3.org/2000/01/rdf-schema#
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
owl	http://www.w3.org/2002/07/owl#
nci	http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#
xsdh	http://www.w3.org/2001/XMLSchema#

Statements

Subject Item: nci:C62482
rdf:type: owl:Class
rdfs:label: Tigatuzumab
rdfs:subClassOf: _:vb655083 _:vb655084 _:vb655085 nci:C20401
nci:A7: nci:C18178
nci:P106: Amino Acid, Peptide, or Protein Immunologic Factor
nci:P108: Tigatuzumab
nci:P207: C2973415
nci:P329: 489323
nci:P330: 489323
nci:P366: CS-1008
nci:P90: <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>CS-1008</n0:term-name><n0:term-group>CN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>anti-[Homo sapiens TNFRSF10B (Tumor Necrosis Factor Receptor Superfamily Member 10B, DR5, TRAIL-R2, CD262)] Humanized Monoclonal TRA-8</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Anti-DR5 MoAb</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Tigatuzumab</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Anti-TRAIL-R2 MoAb</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm>
nci:P97: <n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A humanized agonistic monoclonal antibody directed against human tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) with potential antitumor activity. Mimicking the natural receptor ligand TRAIL, tigatuzumab binds to TRAIL-R2, activating signal transduction pathways that may result in tumor cell apoptosis and a reduction in tumor growth. A member of the tumor necrosis factor (TNF) receptor family, TRAIL-R2, also known as DR5 (death receptor 5), is expressed on the surfaces of many types of malignant cells.</n0:def-definition><n0:def-source>NCI</n0:def-source></n0:ComplexDefinition>
nci:code: C62482

Subject Item: _:vb655083
rdf:type: owl:Restriction
owl:onProperty: nci:R146
owl:someValuesFrom: nci:C18178

Subject Item: _:vb655084
rdf:type: owl:Restriction
owl:onProperty: nci:R125
owl:someValuesFrom: nci:C16298

Subject Item: _:vb655085
rdf:type: owl:Restriction
owl:onProperty: nci:R124
owl:someValuesFrom: nci:C40474